SNORD17-mediated KAT6B mRNA 2’-O-methylation regulates vasculogenic mimicry in glioblastoma cells

Cui, Jingyi; Liu, Xiaobai; Dong, Wei; Liu, Yunhui; Ruan, Xuelei; Zhang, Mengyang; Wang, Ping; Liu, Libo; Xue, Yixue

doi:10.1007/s10565-023-09805-w

Cited by 6 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VEGFR2 is expressed in the vascular endothelium and promotes endothelial proliferation and recruitment and is recognized as a marker of tumor VM. Indeed, VEGFR2 is significantly abnormally high expressed in GBM and promotes VM formation (Yao et al 2013 ; Cui et al 2023 ; Mao et al 2015 ). Guided by these collective insights, we were motivated to investigate the putative functions for NFATC3, FOSL1 and HNRNPA2B1 on VM formation and establish its potential interactions in the context of VEGFR2 expression.…”

Section: Introductionmentioning

confidence: 99%

HNRNPA2B1 stabilizes NFATC3 levels to potentiate its combined actions with FOSL1 to mediate vasculogenic mimicry in GBM cells

Wang,

Shi,

Zhou

et al. 2024

Cell Biol Toxicol

View full text Add to dashboard Cite

Background Vasculogenic mimicry (VM) is an enigmatic physiological feature that influences blood supply within glioblastoma (GBM) tumors for their sustained growth. Previous studies identify NFATC3, FOSL1 and HNRNPA2B1 as significant mediators of VEGFR2, a key player in vasculogenesis, and their molecular relationships may be crucial for VM in GBM. Aims The aim of this study was to understand how NFATC3, FOSL1 and HNRNPA2B1 collectively influence VM in GBM. Methods We have investigated the underlying gene regulatory mechanisms for VM in GBM cell lines U251 and U373 in vitro and in vivo. In vitro cell-based assays were performed to explore the role of NFATC3, FOSL1 and HNRNPA2B1 in GBM cell proliferation, VM and migration, in the context of RNA interference (RNAi)-mediated knockdown alongside corresponding controls. Western blotting and qRT-PCR assays were used to examine VEGFR2 expression levels. CO-IP was employed to detect protein–protein interactions, ChIP was used to detect DNA–protein complexes, and RIP was used to detect RNA–protein complexes. Histochemical staining was used to detect VM tube formation in vivo. Results Focusing on NFATC3, FOSL1 and HNRNPA2B1, we found each was significantly upregulated in GBM and positively correlated with VM-like cellular behaviors in U251 and U373 cell lines. Knockdown of NFATC3, FOSL1 or HNRNPA2B1 each resulted in decreased levels of VEGFR2, a key growth factor gene that drives VM, as well as the inhibition of proliferation, cell migration and extracorporeal VM activity. Chromatin immunoprecipitation (ChIP) studies and luciferase reporter gene assays revealed that NFATC3 binds to the promoter region of VEGFR2 to enhance VEGFR2 gene expression. Notably, FOSL1 interacts with NFATC3 as a co-factor to potentiate the DNA-binding capacity of NFATC3, resulting in enhanced VM-like cellular behaviors. Also, level of NFATC3 protein in cells was enhanced through HNRNPA2B1 binding of NFATC3 mRNA. Furthermore, RNAi-mediated silencing of NFATC3, FOSL1 and HNRNPA2B1 in GBM cells reduced their capacity for tumor formation and VM-like behaviors in vivo. Conclusion Taken together, our findings identify NFATC3 as an important mediator of GBM tumor growth through its molecular and epistatic interactions with HNRNPA2B1 and FOSL1 to influence VEGFR2 expression and VM-like cellular behaviors. Graphical Abstract 1. NFATC3 binds to the promoter region of VEGFR2 to enhance VEGFR2 gene expression which leads to an increase in VM of GBM. 2. FOSL1 interacts with NFATC3 to further facilitate VEGFR2 gene expression and VM. 3. HNRNPA2B1 enhances NFATC3 mRNA stability to increase VEGFR2 expression and VM.

show abstract

Section: Introductionmentioning

confidence: 99%